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Antimicrobial peptides and their 
potential as therapeutic agents 
Introduction 
The rapid and continuous increase of antibiotic resistance has become a global public health problem, conventional antibiotics are becoming ineffective as a result of 
resistance, so there is a need to find new antibacterial strategies and develop a new class of antibiotics.  
Antimicrobial peptides (AMPs) are an evolutionarily conserved component of the innate immune defense system that have raised interest for their ability to kill 
multidrug-resistant microorganisms and represent a promising alternative approach in the treatment of microbial-related diseases.  
Antimicrobial peptides (AMPs) have served as natural first-line of defense system encoded by genes from the majority of living organisms. In mammals are expressed 
in a variety of cell types including monocytes, macrophages, neutrophils, epithelial cells, keratinocyts and mast cells. They may be constitutively expressed or be 
inducible depending on the specific peptide,  specie,  tissue or cell type. 
AMPs are recognized for their potent antimicrobial activity to direct kill, disrupting the membrane of a wide range of microorganisms, such as bacteria, fungi, 
parasites and virus, as well as for their immunomodulatory properties (Fig.1). 
At present, more than 1000 different antimicrobial peptides have been reported from numerous natural biological sources and thousands of synthetic variants have 
been produced. Several AMPs peptides have already entered pre-clinical and clinical trials for the treatment of host disease conditions including microbial infections, 
wound healing or acne. 
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Characteristics that affect antimicrobial activity  
AMPs are relatively short polypeptides with fewer than 60 amino acid residues, 
cationics with an overall positive charge (generally +2 to +9) and with a 
substantial proportion (   30%) of hydrophobic residues due to an excess of 
basic lysine, arginine and histidine residues.  These properties permit the 
peptide to fold into an amphipathic structure in three dimensions.  
 
AMPs Vs Conventional antibiotics 
Limitations Advantages 
The antimicrobial activity involves an 
electrostatic attraction between the AMP and 
the outer microbial membrane (Fig.2). 
Bacterial membranes are negatively charged  
with lipids bearing phospholipids head-groups 
such as PG, CL or SP.  In contrast, the outer layer 
of the mammalian  membranes  are enriched in 
zwitterionic phospholipids (neutral in net 
charge)  as PE, PC, SM. Moreover, the presence 
of cholesterol, a major constituent of 
mammalian cellular membranes, can reduce the 
activity of AMPs stabilizing the lipid bilayer or by 
directly interacting and neutralizing them. 
 
Property Conventionals antibiotics  AMPs 
Spectrum of activity Bacterial infections  
Bacterial, fungal and viral 
infections; sepsis; and/or 
inflammation 
Mechanism and Targets 
Specific mechanisms. Usually one 
dominating target or class of 
targets 
Relatively non-specific mechanism 
(based on charge). Relatively less 
specific (possibly multiple targets in 
any given cell) 
Resistance rate 
Resistance development after a few 
passages at sub-MIC. 
Needs multiple passages on sub-
MIC concentrations to induce 
resistance. 
Pharmacokinetics 
Generally, good bioavailibity and 
biodistribution 
Short systemic half-life owning to 
proteolytic degradation 
Toxicology 
Antibiotics tend to be one of the 
safest group of pharmaceuticals 
No known topical toxicities; 
systemic toxicity issues remain 
undefined 
Manufacturing costs 
Can be inexpensive (e.g. $0,8 for 
aminoglycosides) 
Expensive ( $50-400 per gram) 
   Their ability to kill multi-drug resistant 
bacteria and their low propensity for 
resistance development. 
   Their broad spectrum of activity: Gram- 
negative and gram positive bacteria, virus, 
yeast, protozoa and funghi. 
   Their rapid killing mechanism (minutes 
in vitro). 
   Their diverse potential applications: can 
be used as single antimicrobials, in 
combination with other antibiotics for a 
synergistic effect or as immunomodulatory 
and endotoxin-neutralizing compound.  
 
   The high manufacturing cost of synthetic 
peptides. 
   Systemic and local toxicity. 
   Reduced activity based on salt, serum and 
pH sensibility. 
   Pharmacokinetic and Pharmacodynamic 
issues. 
   Low stability in vivo due to AMPs are 
sensitive toward proteolytic degradation, 
especially their susceptibility to mammalian 
proteases. 
   There are some reports that resistance can 
be developed in response to the use of 
certain AMPs. 
 Conclusions 
Although AMPs possess considerable qualities as new generation antibiotics, their clinical and commercial 
development still have some limitations, but there are several strategies to overcome those obstacles.  Peptide design 
can address lability to proteases by using D-amino acids rather than L-amino acids, employing different backbones 
(peptidomimetics), chemically modifying protease-sensitive sites or delivering the peptides in protective vehicles 
such as liposomes. Regarding their high cost, one cheaper alternative is to synthesize them using recombinant 
expression methods or use conventional or solution-phase peptide synthesis but decreasing the size of the peptides.  
There is a need of more peptide structure-activity studies to increase their tolerability and specificity. Once 
pharmacodynamics will be better understood, dosing regimens can be designed rationally to optimize disease 
outcomes and minimize toxicity problems. 
At industrial level several companies worldwide are focused on the development of AMPs and there are some 
molecules at the preclinical and clinical stage. Their introduction as therapeutics is limited yet and will require 
significant improvements and innovations, but there is still a general optimism for their use in future clinical practice. 
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Figure 2. The membrane target of antimicrobial 
peptides of multicelular organisms and the basis 
of specificity. Figure  from ref. 6. 
Figure1. Biological roles of AMPs: immunomodulatory properties and direct killing by membrane disruptive mechanisms (barrel-








Table 1. Comparison of conventional antibiotic and cationic antimicrobial peptides.  
MIC: Minimal inhibitory concentration 
Bases of their selectivity: electrostatic interaction 
